Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
R3 Vascular Inc. logo — The Next Generation of BTK Interventional Therapies for PAD

R3 Vascular Inc.

The Next Generation of BTK Interventional Therapies for PAD

Founded 2019 United States Mountain View, United States 18 employees Series B Total: $104.80M Health Care, Manufacturing +1

General Information

Company Name R3 Vascular Inc.
Founded Year 2019
Location United States Mountain View, United States +1
Employees 18
Industries Health Care, Manufacturing, Medical Devices
Funding Stage Series B
Social

Get notified when R3 Vascular Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About R3 Vascular Inc.

R3 Vascular Inc. is a privately-held Medical Device company that has developed a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD, affecting 200 million people globally, is primarily caused by the buildup of fatty plaque in the arteries, called atherosclerosis, which narrows or blocks the vessels carrying blood from the heart to the legs or lower extremities. The company's technology is designed to address the increasing burden of risk factors and an aging population, with approximately 6.5 million affected individuals in the United States alone. The R3 Vascular BVS platform offers a promising solution by combining the support of a scaffold with the anti-inflammatory effects of sirolimus, ultimately 'disappearing' over time as the vessel heals. The company, founded in 2019, has its headquarters in Mountain View, Calif., USA, with additional operations in Munich, Germany. Notably, the company secured a significant $17.80M Series A investment from 415 CAPITAL on 08 October 2020. Overall, R3 Vascular presents a compelling proposition in the field of interventional therapies for PAD, addressing a critical global health issue with a promising technology platform. With its recent successful funding round, the company is positioned to advance its innovative solutions and make a meaningful impact in the medical device industry and the treatment of PAD.

Taxonomy: Interventional Therapy, Bioresorbable Vascular Scaffolds, Sirolimus Coating, Peripheral Artery Disease (PAD), Atherosclerosis, Medical Technology, BTK Therapy, Medical Innovations, Cardiovascular Health, Innovative Medical Solutions, Inflammatory Response, Vascular Health, Chronic Disease Management

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 2
Investor Investor
09 May 2024
Series A •••••• 1
Investor
08 Oct 2020

R3 Vascular Inc. Alternatives & Competitors

R3 Vascular Inc. vs
Ashchi Heart & Vascular Center, PA
Ashchi Heart & Vascular Center, PA United States

Providing high quality, diagnostic treatments & services for patients with diseases of the heart & v...

8 employees
Health Care
R3 Vascular Inc. vs
Pacific Vascular, Inc.
Pacific Vascular, Inc. United States

Specialists in Diagnostic Vascular Ultrasound

74 employees
Health Care
R3 Vascular Inc. vs
Pathfinder Medical
Pathfinder Medical United Kingdom

Advancing endovascular procedures (Trading name for Stent Tek Ltd)

Series A
15 employees
Biotechnology

FAQ About R3 Vascular Inc.

The Next Generation of BTK Interventional Therapies for PAD
R3 Vascular Inc. was founded in 2019.
R3 Vascular Inc. is headquartered in Mountain View, United States.
R3 Vascular Inc. operates in the following industries: Health Care, Manufacturing, Medical Devices.
R3 Vascular Inc. has approximately 18 employees.
R3 Vascular Inc. has completed 2 funding rounds, raising a total of $104.80M. The latest funding stage is Series B.
Top alternatives and competitors to R3 Vascular Inc. include Ashchi Heart & Vascular Center, PA, Pacific Vascular, Inc., Pathfinder Medical, Stem Cell Cure India, Ra Medical Systems. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
R3 Vascular Inc. and Ashchi Heart & Vascular Center, PA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors R3 Vascular Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes